Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Preferred Stock Liabilities: 2023-2024

  • Upstream Bio's Preferred Stock Liabilities rose 64.93% to $380.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $380.9 million, marking a year-over-year increase of 64.93%. This contributed to the annual value of $230.9 million for FY2023, which is N/A change from last year.
  • Upstream Bio's Preferred Stock Liabilities amounted to $380.9 million in Q3 2024, which was up 64.93% from $230.9 million recorded in Q4 2023.
  • Upstream Bio's 5-year Preferred Stock Liabilities high stood at $380.9 million for Q3 2024, and its period low was $230.9 million during Q3 2023.
  • Its 2-year average for Preferred Stock Liabilities is $280.9 million, with a median of $230.9 million in 2023.
  • Data for Upstream Bio's Preferred Stock Liabilities shows a peak YoY soared of 64.93% (in 2024) over the last 5 years.
  • Upstream Bio's Preferred Stock Liabilities (Quarterly) stood at $230.9 million in 2023, then skyrocketed by 64.93% to $380.9 million in 2024.
  • Its Preferred Stock Liabilities was $380.9 million in Q3 2024, compared to $230.9 million in Q4 2023 and $230.9 million in Q3 2023.